Introduction

Pathological pain is a common symptom of many conditions, and severely reduces quality of life and health status of millions of patients. It has been shown that adenosine triphosphate (ATP) receptors play important role in neuropathic and inflammatory pain conditions (Chizh and Illes 2001; Burnstock 2009, 2013). Among the ATP receptors, the P2X7 receptor (P2X7R) can form a large, macromolecular pore upon repetitive or prolonged exposure to high concentrations of ATP (North 2002). Moreover, the P2X7R plays an important role in the initiation and maintenance of inflammatory and neuropathic pain (Chizh and Illes 2001; Sperlagh et al. 2006; Skaper et al. 2010). Particularly, recent study indicated that activation of P2X7R in microglial cells of spinal cord contributes to the inflammatory pain induced by BmK I, an activator of sodium channel and major toxin component of the venom of Asian scorpion Buthus martensi Karsch (BmK) (Zhou et al. 2019). In dorsal root ganglion (DRG), P2X7R is selectively expressed in satellite glial cells (SGCs), and is involved in the modulation of nociceptive signals in DRGs (North 2002; Liu and Salter 2005; Nakatsuka and Gu 2006; Chen et al. 2008). For instance, the P2X7R in SGCs promotes the release of pro-inflammatory cytokines, including tumor necrosis factor alpha (TNF-a), interleukin 1 beta (IL-1β) and other molecules that sensitize peripheral sensory nerves.

Electronic supplementary material. The online version of this article (doi: 10.4149/gpb_2019026) contains supplementary material.

doi: 10.4149/gpb_2019026
kin-1 beta (IL-1β) and interleukin-6 (IL-6) (Arulkumaran et al. 2011).

The inflammatory pain behaviors induced by BmK venom include spontaneous pain, ipsilateral thermal hypersensitivity, and bilateral mechanical hypersensitivity in rats (Bai et al. 2010). The active compound BmK I purified from the venom of the BmK plays a major role in the inflammatory pain caused by the BmK venom (Bai et al. 2003, 2010). The bilateral mechanical hypersensitivity is a characteristic feature of pain induced by BmK I venom or BmK I that highlights the importance of utilizing natural toxins in pain models. The DRG neuron is the primary neuron that transmits noxious stimuli from the periphery to the central nervous system (Basbaum et al. 2009). The neuronal soma of DRG neurons communicate bilaterally with their surrounding SGCs in DRGs (Zhang et al. 2007; Chen et al. 2008). However, it is not clear whether or how SGCs might interact with neurons in DRG in the pain model induced by toxins. In the current study, we investigated the role of P2X7R in SGCs of DRG in the BmK I-induced pain model of rat.

Materials and Methods

Experimental animals

Adult male Sprague-Dawley rats (210 ± 10 g) used in this study were provided by Shanghai Experimental Animal Center, Chinese Academy of Sciences. All experiments had been done according to the guidelines of International Association for the Study of Pain (IASP) for pain research in conscious animals. All efforts were made to minimize animal suffering and to reduce the number of animals used.

Preparation and administration of BmK I

Crude BmK venom was purchased from an individual scorpion culture farm in Henan Province, China. BmK I used in this study was purified from the venom of scorpion BmK following the process described by Ji et al. (1996), and then assessed by both mass spectrum and high-performance liquid chromatography. 50 µl of BmK I (0.2 µg/µl in saline) was intraplantarly (i.pl.) injected into the left hind paw (Jiang et al. 2013). Saline solution of the same volume was used in control animals.

Preparation and administration of A-438079

A-438079 (MedChemExpress, Princeton, NJ, USA), an inhibitor of P2X7R was dissolved in saline (30.6 mg/ml, 100 mM). 100 µl of A-438079 (15 mg/kg) was intraperitoneal (i.p.) injected into rats 30 min before BmK I injection.

Behavioral testing

In the study, behavioral tests were used to evaluate the suppressive effect of A-438079 on BmK I-induced pain responses. The measurement of spontaneous nociceptive responses, paw withdrawal mechanical threshold (PWMT) and paw withdrawal thermal latency (PWTL) were performed according to the methods described by Bai et al. (2003).

Measurement of spontaneous nociceptive behaviors

The test box with a glass floor was placed on a steel frame above the experimental table covered with a mirror. Before administration, rats were placed in the test box separately for habituation. 30 min after the i.p. injection of A-438079, BmK I was injected into the rats’ left hind paws. Spontaneous nociceptive behaviors are determined by the number of the injected hind paw flinches during 5 min interval for 2 h (Chen et al. 1999). Evaluation of spontaneous nociceptive behaviors was performed by an experimenter unaware of the experimental condition.

Measurement of PWMT

Mechanical sensitivity was detected by using a series of 10 calibrated von Frey filaments with forces ranging from 0.6 to 26 g (58011, Stoelting Co, Wood Dale, Illinois, USA). Each filament was applied bilaterally to hind paws, and was probed for same duration of 2–3 s with an inter-stimulus interval of 10 s. The positive response was indicated by brisk withdrawal and/or flinching. Each subject’s PWMT was defined as the lowest force that caused at least five withdrawals out of ten consecutive applications (Chen et al. 1999). Baseline PWMT measures for each subject were taken 24 h prior to testing. Evaluation of PWMT was performed by an experimenter unaware of the experimental condition.

Measurement of PWTL

Each subject’s PWTL to radiant heat stimuli was determined as previously described (Hargreaves et al. 1988). Heat stimuli were provided with radiant heat stimulator (RTY-3, Xi’an Fenglan Instrument Factory, Xi’an, Shaanxi province, China). The heat source was a high intensity projector halogen lamp bulb (150 W, 24 V). For one rat, five stimuli were performed with a stimuli interval of 10 min, and the rat’s PWTL was determined by averaging the last three values of the five consecutive stimuli. Baseline PWTL measures were taken 24 h before testing. Evaluation of PWTL was performed by an experimenter unaware of the experimental condition.
Western blot

At different time points (1, 2, 4, 8, and 24 h) after i.p. BmK I injection, the rats were anesthetized with i.p. injection of sodium pentobarbital (60 mg/kg) (BmK I group), while naive rats were considered as control group. The L4–L5 DRGs protein lapping liquids were obtained by homogenization in ice-cold RIP A Lysin Buffer (Beyotime, Shanghai, China). After 30 min ice-water bath and centrifugation at 14000 rpm for 15 min, the supernate containing total cellular protein was collected. Then each protein concentrations were measured by Bradford Protein Assay Kit (Beyotime, Shanghai, China). Finally, SDS-PAGE Sample Loading Buffer was mixed into the supernate by proportion until heated for 5 min at boiling water. Protein samples (45 μg) were separated on 5% SDS-PAGE and blotted on a PVDF membrane (0.45 μm; Millipore, Billerica, Massachusetts, USA). The membranes were then incubated in 5% non-fat milk at room temperature for 2 h. The primary antibodies listed in supplement were then individually diluted in PBS with Tween-20 (0.05%PBST) containing 1% BSA and incubated overnight at 4°C.

The blots were detected in ECL detection reagent (WB-KLS0050; Millipore, Billerica, Massachusetts, USA) with a fully automatic chemiluminescence image analysis system (Tanon-5200; Tanon Science & Technology Co, Ltd, Shanghai, China). The bands were captured using the Image J (National Institutes of Health, Bethesda, Maryland, USA).

Immunohistochemistry

Rats were anesthetized and perfused intracardially with 200 ml sterile saline after i.pl. injection of BmK I at different time points (2, 4, 8, and 24 h), followed by 400 ml fixative containing 4% paraformaldehyde in 0.1 M phosphate buffer (PBS; pH 7.4). Bilateral DRGs from L4–L5 were post-fixed in 0.1 M PBS containing 20% sucrose for dehydration until precipitates, then DRG tissues were cryoprotected in 0.1 mol/l PBS containing 30% sucrose until they subsided at 4°C. Then each protein concentrations were measured by Bradford Protein Assay Kit (Beyotime, Shanghai, China). Finally, SDS-PAGE Sample Loading Buffer was mixed into the supernate by proportion until heated for 5 min at boiling water. Protein samples (45 μg) were separated on 5% SDS-PAGE and blotted on a PVDF membrane (0.45 μm; Millipore, Billerica, Massachusetts, USA). The membranes were then incubated in 5% non-fat milk at room temperature for 2 h. The primary antibodies listed in supplement were then individually diluted in PBS with Tween-20 (0.05%PBST) containing 1% BSA and incubated overnight at 4°C.

The blots were detected in ECL detection reagent (WB-KLS0050; Millipore, Billerica, Massachusetts, USA) with a fully automatic chemiluminescence image analysis system (Tanon-5200; Tanon Science & Technology Co, Ltd, Shanghai, China). The bands were captured using the Image J (National Institutes of Health, Bethesda, Maryland, USA).

Real-time quantitative polymerase chain reaction

1, 2, 4, 8, and 24 h after i.pl. injection of 50 μl diluted BmK I solution (0.2 μg/μl) into adult male rats (n = 4 for each group), total RNA was isolated from bilateral L4–L5 DRGs with Total RNA Extractor (Trizol) (Sangon Biotech, Shanghai, China). Then the RNA was reverse-transcribed with Prime-Script® RT Master Mix (TaKaRa, Dalian, China). Primer sequences targeted to P2X7R were designed by Primer Premier 6.0 software (Premier Biosoftware, California, USA) while the primers for β-actin was designed referring to a previous publication (Qin et al. 2017). The primer sequences are listed in Supplementary materials.

Quantitative PCR was performed by CFX Connect™ Real-Time PCR System (Bio-Rad, California, USA) in SYBR® prime Ex Taq™ (TaKaRa, Dalian, China). The P2X7 subtypes mRNA was normalized to the β-actin mRNA level and the data were analyzed using the 2−ΔΔCt method (Adnan et al. 2011).

Statistical analysis

All results were expressed as mean ± SEM (standard error of the mean) and analyzed by GraphPad Prism 6 software (GraphPad Software, Inc, La Jolla, California, USA). Data of immunostaining also used the Image-Pro Plus 6.0 software (Media Cybernetics, Inc, Rockville, Maryland, USA). The differences between groups were compared by Two-way ANOVA followed by Dunnett’s post hoc test. The data of behavior tests were analyzed using One-way ANOVA followed by a Dunnett’s post hoc test and Two-way ANOVA followed by a Bonferroni’s post hoc test. The relative densities of Western blots were analyzed by one-way ANOVA followed by Dunnett’s post hoc test and One-way ANOVA followed by a Tukey’s post hoc test, p < 0.05 was considered to be statistically significant.

Results

Effects of BmK I on P2X7R in SGCs of DRG

Immunohistochemistry experiments were conducted to study the effects of BmK I on the expression of P2X7R in DRG. Immunoreactivity (IR) for P2X7R was stronger at the ipsilateral DRG of BmK I group (Fig. 1B–E, G–J) compared to the control group (Fig. 1A, F) following BmK I injection. The increase in the P2X7R reactivity started from 2 h after BmK I injection (Fig. 1B), reached a peak at 4 h (Fig. 1C), decreased at 8 h (Fig. 1D), and further decreased at 24 h (Fig. 1E). On the other hand, the staining of contralateral P2X7R did not have significant change during the same period (Fig. 1G–J, M).
The protein expression levels of the P2X7R in the DRG were further analyzed by Western blot analysis. The expression of P2X7R in the BmK I group was significantly increased compared to the control group. The P2X7R in the ipsilateral dorsal root ganglia was significantly increased at 2, 4, and 8 h after BmK I administration (Fig. 1K). Compared to the ipsilateral side (Fig. 1K), a significant change of P2X7R expression was only observed at 4 h after BmK I injection at the contralateral side of the dorsal root ganglia (Fig. 1L). Moreover, the increase at 4 h after BmK I injection was more than 2× larger at the ipsilateral side compared to contralateral side of DRG.

To study if transcriptional mechanism might be involved in the increase of P2X7R receptors, we also performed qPCR experiments to study the mRNA expression of P2X7R. It was observed that mRNA expression of P2X7R was selectively increased at the ipsilateral side, but not the contralateral side of DRG at 4 and 8 h after BmK I administration (Fig. 1N, O).

To study if transcriptional mechanism might be involved in the increase of P2X7R receptors, we also performed qPCR experiments to study the mRNA expression of P2X7R. It was observed that mRNA expression of P2X7R was selectively increased at the ipsilateral side, but not the contralateral side of DRG at 4 and 8 h after BmK I administration (Fig. 1N, O).

Effects of BmK I on IL-1β in DRG

The immunoreactivity of IL-1β was studied in DRG 4 h after BmK I administration. In the sections of the L4-5 dorsal root ganglia from the control rats (Fig. 3A and B), only few immunoreactivity for IL-1β could be detected. The immunoreactivity of IL-1β increased significantly after BmK I administration (Fig. 3C–F).

The protein expression of IL-1β in DRG was further detected by Western blot. It was found that IL-1β was increased at both sides of DRG after BmK I injection (Fig. 3G–H). Compared to the control group, a significant increase of IL-1β was detected at 4 h after BmK I administration.

Effects of a P2X7R antagonist A-438079 on BmK I-induced pain behaviors

To study the functional relevance of P2X7R in the development of BmK I-induced pain, we examined whether A-438079 reduces the BmK I-induced pain behaviors. We administrated the A-438079 (100 μM, i.p.) 30 minutes before BmK I or saline administration. Compared to the control group, 100 μM A-438079 significantly suppressed the spontaneous pain responses (Fig. 4A, B). The suppression of flinches by A-438079 lasted for 2 h (Fig. 4A). Furthermore, the BmK I-induced hypersensitivity was also reduced by A-438079. Bilateral mechanical hypersensitivity (Fig. 4C, D) and ipsilateral thermal

Figure 1. BmK I up-regulates the expression of P2X7R in DRG. Spatiotemporal distribution of P2X7Rs in DRG following the injection of BmK I (A–J). Compared with the control group (A, F), BmK I-treated groups (B–E, G–J) showed largely increased P2X7R immunoreactivity in the ipsilateral DRGs. Increased ipsilateral P2X7R immunoreactivity began at 2 h and peaked at 4 h following the administration of BmK I. Scale bar: 100 μm (A–J). Statistic results of P2X7R expression in bilateral DRG (M; n = 3; * p < 0.05, ** p < 0.01 compared with control, two-way ANOVA, Dunnett’s post hoc test; error bars indicate SEM). Western blots and analysis of P2X7Rs in DRG after i.pl. injection of BmK I (K, L). Representative Western blots show levels of P2X7R and β-actin in both ipsilateral (K) and contralateral (L) sides of DRG; columns represent the mean levels with respect to each control group at different time points after i.pl. BmK I injection. QPCR results of P2X7R mRNA expression on the ipsilateral (N) and contralateral (O) sides of DRG (n = 3; * p < 0.05, ** p < 0.01 compared with control group and assessed using a One-way ANOVA, Dunnett’s post hoc test; error bars indicate SEM).
hypersensitivity (Fig. 4E) were reduced at 4 h and 8 h after BmK I administration. However, A-438079 had no effects on the contralateral thermal sensitivity (Fig. 4F).

Discussion

DRG neurons produce primary sensory action potentials upon peripheral stimuli and transmit the action potential signal to the spinal cord. The P2X7 receptor in DRG modulates afferent nerve activation and is involved in both neuropathic (Xie et al. 2017; Wu et al. 2017a) and inflammatory pain conditions (Liu et al. 2017). Our recent study indicates that activation of P2X7R in microglial cells of spinal cord contributes to the inflammatory pain induced by BmK I (Zhou et al. 2019). In the present study, we examined the expression of P2X7 receptors in the SGCs of DRG in the BmK I-induced pain model.

Both mRNA and immunohistochemistry experiments found that the P2X7R was significantly increased at the ipsilateral side, but not contralateral side of DRG. However, the increase at the contralateral side was moderate compared to the ipsilateral side. These results suggest that BmK I induces profound and preferential increases in the P2X7R at the injection side of DRG. Moreover, the increase in the P2X7R was 2–8 hours after BmK I injection. Therefore, it is suggested that BmK I induces a transient activation of P2X7 receptors. Double staining experiments found that the P2X7R was co-localized with GFAP suggesting that BmK I activates the P2X7R in the SGCs. Taken together, it is suggested that BmK I induces a transient, ipsilateral side preferentially increase in the expression of P2X7R in the SGCs of DRG in rats.

Notably, our results indicate that the BmK I-induced increase in the mRNA expression is earlier than that in the protein expression of P2X7R (Fig. 1N, K). This phenomenon suggests that a post-transcriptional mechanism that enhances translation of P2X7R mRNA might be involved in the early up-regulation of P2X7R protein induced by BmK I. On the other hand, the BmK I-induced increase in mRNA peaked at 8 h while the increase in protein peaked at 4 h (Fig. 1N, K). This result suggests a negative post-transcriptional mechanism might be also involved in the modulation of BmK I on the expression of P2X7R. Interestingly, a brain

Figure 2. Cellular localization of P2X7R in DRG. Double immunofluorescence of P2X7R in DRG after *i.pl.* administration of BmK I. A, D. The positive staining of P2X7R. B, E. The positive staining of GFAP. C, F. The colocalization of P2X7R with GFAP. Scale bars: 50 μm (A–F).
enriched microRNA, miR-22 was recently identified to control the expression of P2X7R in hippocampus. It can selectively silence the mRNA of P2X7R resulting in the decreased expression of protein, but not mRNA level of P2X7R (Jimenez-Mateos et al. 2015; Engel et al. 2017). It might be suspected that there may be a similar post-transcriptional feedback mechanism in DRG which inhibits the continual increasing of P2X7R protein in the BmK I model.

It has been generally assumed that pro-inflammatory cytokines, including IL-1β and TNF-α, play an important role in the initiation and maintenance of inflammatory (Albuquerque et al. 2017) and neuropathic pain (Xie et al.

Figure 3. Effects of BmK I on the release of IL-1β in DRG. Immunoreactivity of IL-1β (A–F) and Western blot results of IL-1β expression (G, H) in DRG in the presence of BmK I. Immunoreactivity of IL-1β in the rat DRG following the injection of BmK I. (A–F) Compared with the saline group (A–B), bilateral IL-1β immunoreactivity of DRG increased significantly in BmK I-treated rats (C–F). White open squares (in C, D) indicate the corresponding scope of the amplified images (E, F) in the confocal images. Scale bars: 100 μm (A–D); 50 μm (E, F). Western blot analysis of IL-1β in DRG in the presence of BmK I (G, H). Representative Western blots showing levels of IL-1β and β-actin in both ipsilateral (G) and contralateral (H) sides of DRG, bar graphs represent the mean levels with respect to each control group at different time points after i.pl. BmK I injection. The data are presented as mean ± S.E.M. * $p < 0.05$, ** $p < 0.001$ ($n = 3$), when compared with control group and assessed using a one-way ANOVA, followed by Dunnett’s post hoc test.
It has been demonstrated that P2X7 receptors can mediate the release of IL-1β (Burnstock and Knight 2018). Our results found that the expression of IL-1β was increased in the BmK I-induced rats. Therefore, it was suggested that the activation of the P2X7R might lead to the release of IL-1β in the DRG following BmK I injection. However, our results found that the increase in IL-1β was similar between ipsilateral and contralateral sides while the increase in P2X7R was preferentially on the ipsilateral side. The results suggest that BmK I-induced up-regulation of P2X7R might preferentially contribute to the release of IL-1β at the ipsilateral side of DRG, and that there might have other mechanism contributing to the up-regulation of IL-1β at the contralateral side of DRG.

In addition to the increased expression of P2X7R and IL-1β in DRG, we also found that systemic administration of A-438079 reduced both evoked and spontaneous pain behaviors induced by BmK I. These results suggest that P2X7R in SGCs of DRG might contribute to the pain hypersensitivity in the BmK I-induced pain model. Moreover, our recent study suggested that microglial P2X7R in spinal cord might contribute to the BmK I-induced pain. Therefore, both P2X7R
in SGCs of DRG and in microglial cells of spinal cord might contribute to the pain hypersensitivity induced by BmK I.

The effects of peripheral SGCs on pain have been studied in the DRG (Hanani et al. 2002; Hanani 2005). Spontaneous pain activity originating at the injured side or DRG neurons may be a cause of glial activation (Chung and Chung 2002; Xie et al. 2009). It is well known that the soma of neurons in primary sensory ganglia are tightly enwrapped by SGCs. The SGCs in DRG express P2X7 receptors (Gu et al. 2010; Chen et al. 2012; Puchalowicz et al. 2015) and can communicate with neurons by signaling molecules. P2X7Rs in SGCs are endogenously active in the DRG (Chen et al. 2008; Huang et al. 2013). Therefore, increased P2X7Rs in SGCs of DRG might contribute to the activation of SGCs following BmK I injection. Activated SGCs might release excitatory neuropeptides such as IL-1β that can increase the excitability of DRG neurons, and the pain sensitivity in the BmK I pain model.

Conclusion

In conclusion, the present study provides first evidence to support an involvement of peripheral P2X7R (expressed in the SGCs in DRG) in the pain induced by a toxin (BmK I).

Conflict of interest. No potential conflict of interest was reported by the authors.

Acknowledgements. This work was supported by grants from National Natural Science Foundation of China (31571032, 31771191). Z.T. was supported by an Indiana Spinal Cord and Brain Injury Research Fund (2017). The authors thank Mrs. Renqi Wu for her technical assistance.

References

Adnan M, Morton G, Hadi S (2011): Analysis of rpoS and bolA gene expression under various stress-induced environments in planktonic and biofilm phase using 2(-Delta Delta CT) method. Mol. Cell. Biochem. 357, 275-282
Albuquerque AFM, Fonteles CSR, Do Val DR, Chaves HV, Bezerra MM, Pereira KMA, De Barros Silva PG, De Lima BB, Soares ECS, Ribeiro TR, Costa FWG (2017): Effect of pre-emptive analgesia on clinical parameters and tissue levels of TNF-alpha and IL-1beta in third molar surgery: a triple-blind, randomized, placebo-controlled study. Int. J. Oral Maxillofac. Surg. 46, 1615-1625
Arulkumaran N, Unwin RJ, Tam FW (2011): A potential therapeutic role for P2X7 receptor (P2X7R) antagonists in the treatment of inflammatory diseases. Expert. Opin. Investig. Drugs 20, 897-915
Bai ZT, Zhang XY, Ji YH (2003): Fos expression in rat spinal cord induced by peripheral injection of BmK I, an alpha-like scorpion neurotoxin. Toxicol. Appl. Pharmacol. 192, 78-85
Bai ZT, Liu T, Jiang F, Cheng M, Pang XY, Hua LM, Shi J, Zhou JJ, Shu XQ, Zhang J, Ji YH (2010): Phenotypes and peripheral mechanisms underlying inflammatory pain-related behaviors induced by BmK I, a modulator of sodium channels. Exp. Neurol. 226, 159-172
Basaiba AI, Bautista DM, Scherrer G, Julius D (2009): Cellular and molecular mechanisms of pain. Cell 139, 267-284
Burnstock G (2009): Purinergic receptors and pain. Curr. Pharm. Des. 15, 1717-1735
Burnstock G (2013): Purinergic mechanisms and pain--an update. Eur. J. Pharmacol. 716, 24-40
Burnstock G, Knight GE (2016): The potential of P2X7 receptors as a therapeutic target, including inflammation and tumour progression. Purinergic Signal. 14, 1-18
Chen J, Luo C, Li H, Chen H (1999): Primary hyperalgesia to mechanical and heat stimuli following subcutaneous bee venom injection into the plantar surface of hindpaw in the conscious rat: a comparative study with the formalin test. Pain 83, 67-76
Chen Y, Zhang X, Wang C, Li G, Gu Y, Huang LY (2008): Activation of P2X7 receptors in glial satellite cells reduces pain through downregulation of P2X3 receptors in nociceptive neurons. Proc. Nat. Acad. Sci. USA 105, 16773-16778
Chen Y, Li G, Huang LY (2012): P2X7 receptors in satellite glial cells mediate high functional expression of P2X3 receptors in immature dorsal root ganglion neurons. Mol. Pain 8, 9
Chizh BA, Illes P (2001): P2X receptors and nociception. Pharmacol Rev. 53, 553-568
Chung JM, Chung K (2002): Importance of hyperexcitability of DRG neurons in neuropathic pain. Pain Pract. 2, 87-97
Engel T, Brennan GP, Sanz-Rodriguez A, Alves M, Beamer E, Wat...
Hanani M (2005): Satellite glial cells in sensory ganglia: from form to function. Brain Res. Brain Res. Rev. 48, 457-476. https://doi.org/10.1016/j.brainresrev.2004.09.001
Hargreaves K, Dubner R, Brown F, Flores C, Ioris J (1988): A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 32, 77-88. https://doi.org/10.1016/0304-3959(88)90026-7
Huang LY, Gu Y, Chen Y (2013): Communication between neuronal somata and satellite glial cells in sensory ganglia. Glia 61, 1571-1581. https://doi.org/10.1002/glia.22541
Ji YH, Mansuelle P, Terakawa S, Kopeyan C, Yanaihara N, Hsu K, Rochat H (1996): Two neurotoxins (BmK I and BmK II) from the venom of the scorpion Buthus martensi Karsch: purification, amino acid sequences and assessment of specific activity. Toxicon 34, 987-1001. https://doi.org/10.1016/0041-0101(96)00065-7
Jiang F, Pang XY, Niu QS, Hua LM, Cheng M, Ji YH (2013): Activation of mammalian target of rapamycin mediates rat pain-related responses induced by BmK I, a sodium channel-specific modulator. Mol. Pain 9, 50. https://doi.org/10.1186/1744-0699-9-50
Jimenez-Mateos EM, Arribas-Blazquez M, Sanz-Rodriguez A, Connannon C, Olivos-Ore LA, Reschke CR, Mooney CM, Mooney C, Lugara E, Morgan J, et al. (2015): microRNA targeting of the P2X7 purinoceptor opposes a contralateral epileptogenic focus in the hippocampus. Sci. Rep. 5, 17486. https://doi.org/10.1038/srep17486
Liu C, Tao J, Wu H, Yang Y, Chen Q, Deng Z, Liu J, Xu C (2017): Effects of LncRNA BC168687 siRNA on Diabetic Neuropathic Pain Mediated by P2X7 Receptor on SGCs in DRG of Rats. Biomed. Res. Int. 2017, 7831251. https://doi.org/10.1155/2017/7831251
Liu XI, Salter MW (2005): Purines and pain mechanisms: recent developments. Curr. Opin. Investig. Drugs 6, 65-75
Nakatsuka T, Gu JG. (2006): P2X purinoceptors and sensory transmission. Pflugers Arch. 452, 598-607. https://doi.org/10.1007/s00424-006-0057-6
North RA (2002): Molecular physiology of P2X receptors. Physiol. Rev. 82, 1013-1067. https://doi.org/10.1152/physrev.00015.2002
Puchalowicz K, Baranowska-Bosiacka I, Dziedziejko V, Chłubek D (2015): Purinergic signaling and the functioning of the nervous system cells. Cell. Mol. Biol. Lett. 20, 867-918. https://doi.org/10.1151/cmble-2015-0050
Qin S, Jang F, Zhou Y, Zhou G, Ye P, Ji Y (2017): Local knockdown of Nav1.6 relieves pain behaviors induced by BmK I. Acta Biochim. Biophys. Sin. (Shanghai) 49, 713-721. https://doi.org/10.1093/abbs/gmx064
Skaper SD, Debetto P, Giusti P (2010): The P2X7 purinergic receptor: from physiology to neurological disorders. FASEB J. 24, 337-345. https://doi.org/10.1096/fj.09-138883
Sperlagh B, Vizi ES, Wirkner K, Illes P (2006): P2X7 receptors in the nervous system. Prog. Neurobiol. 78, 327-346. https://doi.org/10.1016/j.pneurobio.2006.03.007
Wu B, Ma Y, Yi Z, Liu S, Ruo S, Zou L, Wang S, Xue Y, Jia T, Zhao S, et al. (2017a): Resveratrol-decreased hyperalgesia mediated by the P2X7 receptor in gp120-treated rats. Mol. Pain 2017, 13. https://doi.org/10.1177/1744806917707667
Wu B, Peng L, Xie J, Zou L, Zhu Q, Jiang H, Yi Z, Wang S, Xue Y, Gao Y, et al. (2017b): The P2X7 receptor in dorsal root ganglia is involved in HIV gp120-associated neuropathic pain. Brain Res. Bull. 135, 25-32. https://doi.org/10.1016/j.brainresbull.2017.09.006
Xie J, Liu S, Wu B, Li G, Rao S, Zou L, Yi Z, Zhang C, Jia T, Zhao S, et al. (2017): The protective effect of resveratrol in the transmission of neuropathic pain mediated by the P2X7 receptor in the dorsal root ganglia. Neurochem. Int. 103, 24-35. https://doi.org/10.1016/j.neuint.2016.12.006
Xie W, Strong JA, Zhang JM (2009): Early blockade of injured primary sensory afferents reduces glial cell activation in two rat neuropathic pain models. Neuroscience 160, 847-857. https://doi.org/10.1016/j.neuroscience.2009.03.016
Zhang X, Chen Y, Wang C, Huang LY (2007): Neuronal somatic ATP release triggers neuron-satellite glial cell communication in dorsal root ganglia. Proc. Nat. Acad. Sci. USA 104, 9864-9869. https://doi.org/10.1073/pnas.0611048104
Zhou J, Zhang X, Zhou Y, Wu B, Tan ZY (2019): Up-regulation of P2X7 Receptors Contributes to Spinal Microglial Activation and the Development of Pain Induced by BmK-I. Neurosci. Bull. 35, 624-636. https://doi.org/10.1007/s12264-019-00345-0

Received: April 17, 2019
Final version accepted: July 7, 2019
Supplementary Material

Involvement of P2X7 receptors in satellite glial cells of dorsal root ganglia in the BmK I-induced pain model of rats

Jingjing Zhou¹, Danting Feng¹, Xiaoxue Zhang¹, Chenchen Xia¹, Zhiping Zhang¹, Jiahao Kang¹, Zhiyong Tan² and Bin Wu¹,²

¹ Laboratory of Neuropharmacology and Neurotoxicology, Shanghai University, Shanghai 200444, P. R. China
² Department of Pharmacology and Toxicology, Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA

The antibodies we used in Western blot were listed as following: rabbit polyclonal antibody against P2X7R (1:1000; ab109054; Abcam, Cambridge, Massachusetts, USA), rabbit polyclonal antibody against IL-1β (1:1500; ab9722; Abcam, Cambridge, Massachusetts, USA), rabbit polyclonal antibody against actin (1:200; sc-1616, Santa Cruz Biotechnology, Inc., Dallas, Texas, USA). After washing in PBS, membranes were probed with goat anti-rabbit IgG (H+L) antibody HRP conjugated (1:10000; PAB002; Promotion Co.Ltd., Shanghai, China) for 2 h at room temperature.

The primary antibodies used in immunohistochemistry were showed as follows: rabbit polyclonal to P2X7R (1:400; ab109054; Abcam, Cambridge, Massachusetts, USA), rabbit polyclonal to IL-1β (1:400; ab9722; Abcam, Cambridge, Massachusetts, USA), mouse monoclonal to GFAP (1:300; GA5; Cell Signaling Technology, Danvers, Massachusetts, USA). The secondary antibodies used in immunohistochemistry were showed as follows: donkey anti-rabbit IgG H&L (AlexaFluor®555) (1:300; ab150074, Abcam, Cambridge, Massachusetts, USA), donkey anti-mouse IgG H&L (AlexaFluor®488) (1:300, ab150105, Abcam, Cambridge, Massachusetts, USA) and donkey anti-rabbit IgG-CFL 488 (1:200, sc-362261, Santa Cruz Biotechnology, Inc., Dallas, Texas, USA).

The PCR primers sequences used in RT-PCR were described as follows: P2X7-S: 5’-ACATCCTGGTTTTCGCACT-3’; P2X7-A:5’-AGGGCTCACAGCACTTACAG-3’; β-actin-S:5’-AGCACCTGTGGGCATAGAGGTC-3’; β-actin-A:5’-ACTATCGGCAATGAGCGGTTCC-3’. All primers were synthesized by Sangon Biotech (Shanghai, China).